Pharmaceutical

Dragonfly and Gilead enter partnership for cancer therapy

Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.

Feb 16, 2024 - 18:00
Dragonfly and Gilead enter partnership for cancer therapy
Dragonfly Therapeutics has entered a clinical collaboration with Gilead Sciences to assess DF1001 plus Trodelvy for cancer indications.
Read the original article

Tags:

Previous Article

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Next Article

FDA grants orphan drug status to Ionis’ olezarsen for FCS treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Does the risk of getting long Covid increase each time you get reinfected?

Does the risk of getting long Covid increase each time ...

Sep 20, 2023

STAT+: States are ramping up scrutiny of health transactions, as more provider groups look for buyers

STAT+: States are ramping up scrutiny of health transac...

Feb 13, 2024

STAT+: As the obesity drug market grows, digital health companies juggle patients and payers

STAT+: As the obesity drug market grows, digital health...

Aug 21, 2023